Table 1.
VISTA on immune cells and clinicopathological characteristics in TNBC.
| Parameters | VISTA on immune cells | ||||||
|---|---|---|---|---|---|---|---|
| Negative | Positive | p value | |||||
| N | % | N | % | N | % | ||
| Age | 0.501 | ||||||
| < 50 years | 145 | 57.1 | 66 | 59.5 | 79 | 55.2 | |
| ≥ 50 years | 109 | 42.9 | 45 | 40.5 | 64 | 44.8 | |
| Tumor stage | 0.907 | ||||||
| pT1 | 120 | 47.2 | 52 | 46.8 | 68 | 47.6 | |
| pT2 | 120 | 47.2 | 52 | 46.8 | 68 | 47.6 | |
| pT3 | 9 | 3.6 | 4 | 3.6 | 5 | 3.5 | |
| pT4 | 5 | 2 | 3 | 2.8 | 2 | 1.3 | |
| Lymph node | <0.001 | ||||||
| pN0 | 146 | 57.5 | 53 | 47.7 | 93 | 65 | |
| pN1 | 55 | 21.7 | 22 | 19.8 | 33 | 23.1 | |
| pN2 | 23 | 9.1 | 19 | 17.1 | 4 | 2.8 | |
| pN3 | 30 | 11.7 | 17 | 15.4 | 13 | 9.1 | |
| AJCC stage | 0.001 | ||||||
| I | 83 | 32.7 | 30 | 27 | 53 | 37.1 | |
| II | 116 | 45.7 | 45 | 40.5 | 71 | 49.7 | |
| III | 55 | 21.6 | 36 | 32.5 | 19 | 13.2 | |
| Ki 67 | 0.737 | ||||||
| < 14% | 39 | 15.4 | 18 | 16.2 | 21 | 14.7 | |
| ≥ 14% | 215 | 84.6 | 93 | 83.8 | 122 | 85.3 | |
| Differentiation | 0.08 | ||||||
| Well | 2 | 0.8 | 0 | 0 | 2 | 1.4 | |
| Moderate | 67 | 26.4 | 36 | 32.4 | 31 | 21.7 | |
| Poor | 185 | 72.8 | 75 | 67.6 | 110 | 76.9 | |
| Basal like | <0.001 | ||||||
| Yes | 223 | 87.8 | 86 | 77.5 | 137 | 95.8 | |
| No | 31 | 12.2 | 25 | 22.5 | 6 | 4.2 | |
| VISTA on TCs | 0.423 | ||||||
| Positive | 47 | 18.5 | 23 | 20.7 | 24 | 16.8 | |
| Negative | 207 | 81.5 | 88 | 79.3 | 119 | 83.2 | |
VISTA, V-domain Ig suppressor of T-cell activation; TNBC, triple-negative breast cancer; AJCC, American Joint Committee on Cancer; TC, tumor cell.